What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Journal of Travel Medicine
Volume 28, Issue 4, May 2021
https://academic.oup.com/jtm/issue

 

Perspectives
What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
Yinglian Hu, PhD, Simiao Chen, ScD
Journal of Travel Medicine, Volume 28, Issue 4, May 2021, taab026, https://doi.org/10.1093/jtm/taab026
Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.